Integration of autoencoder and graph convolutional network for predicting breast cancer drug response.

Breast cancer is the most prevalent type of cancer among women. The effectiveness of anticancer pharmacological therapy may get adversely affected by tumor heterogeneity that includes genetic and transcriptomic features. This leads to clinical variability in patient response to therapeutic drugs. Anticancer drug design and cancer understanding require precise identification of cancer drug responses. The performance of drug response prediction models can be improved by integrating multi-omics data and drug structure data. In this paper, we propose an Autoencoder (AE) and Graph Convolutional Network (AGCN) for drug response prediction, which integrates multi-omics data and drug structure data. Specifically, we first converted the high dimensional representation of each omic data to a lower dimensional representation using an AE for each omic data set. Subsequently, these individual features are combined with drug structure data obtained using a Graph Convolutional Network and given to a Convolutional Neural Network to calculate IC[Formula: see text] values for every combination of cell lines and drugs. Then a threshold IC[Formula: see text] value is obtained for each drug by performing K-means clustering of their known IC[Formula: see text] values. Finally, with the help of this threshold value, cell lines are classified as either sensitive or resistant to each drug. Experimental results indicate that AGCN has an accuracy of 0.82 and performs better than many existing methods. In addition to that, we have done external validation of AGCN using data taken from The Cancer Genome Atlas (TCGA) clinical database, and we got an accuracy of 0.91. According to the results obtained, concatenating multi-omics data with drug structure data using AGCN for drug response prediction tasks greatly improves the accuracy of the prediction task.